Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients

Pharmacogenomics

Volumn 15, Issue 10, 2014, Pages 1355-1364

  Gravia, Aikaterini ^a   Chondrou, Vasiliki ^a   Sgourou, Argyro ^b   Papantoni, Ioanna ^a   Borg, Joseph ^c,d   Katsila, Theodora ^a   Papachatzopoulou, Adamantia ^e   Patrinos, George P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b HELLENIC OPEN UNIVERSITY   (Greece)

^c UNIVERSITY OF MALTA   (Malta)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PATRAS   (Greece)

Author keywords

genotyping; hydroxyurea; pharmacogenomics; sickle cell disease; single nucleotide polymorphisms; thalassemia

Indexed keywords

HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HYDROXYUREA;

BETA GLOBIN GENE; BETA THALASSEMIA; BETA TYPE HEMOGLOBINOPATHY; DNA METHYLATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; EPIGENETICS; GENE CLUSTER; GENETIC DISORDER; GENETIC LINKAGE; GENETIC MARKER; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; MODIFIER GENE; NONTRANSFUSION DEPENDENT THALASSEMIA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROSPECTIVE STUDY; PUBLIC HEALTH PROBLEM; RETROSPECTIVE STUDY; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA; THALASSEMIA MAJOR; BETA-THALASSEMIA; GENETICS; PATHOLOGY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906688760     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.101     Document Type: Review

References (47)

1. Patrinos GP, Antonarakis SE. Human Hemoglobin. Springer-Verlag, Berlin, Germany, 36 (2010).
2. Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev. Dyn. 235(7), 1727-1737 (2006). (Pubitemid 43902333)
3. Schechter AN. Hemoglobin research and the origins of molecular medicine. Blood 112(10), 3927-3938 (2008).
4. Weatherall DJ. Towards molecular medicine; reminiscences of the haemoglobin field, 1960-2000. Br. J. Haematol. 115(4), 729-738 (2001). (Pubitemid 34042887)
5. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl. Int. 108(31-32), 532-540 (2011).
6. Higgs DR. The molecular basis of α-thalassemia. Cold Spring Harb. Perspect. Med. 3(1), a011718 (2013).
7. Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harb. Perspect. Med. 2(12), a011726 (2012).
8. Angelucci E, Matthes-Martin S, Baronciani D et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99(5), 811-820 (2014).
9. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J. Pediatr. Hematol. Oncol. 27(7), 380-385 (2005). (Pubitemid 41077027)
10. Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin 32(1-2), 229-236 (2008). (Pubitemid 351264530)
11. Italia KY, Jijina FJ, Merchant R et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin. Chim. Acta 407(1-2), 10-15 (2009).
12. Karimi M, Cohan N, Mousavizadeh K, Moosavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. Pediatr. Hematol. Oncol. 27(3), 205-211 (2010).
13. Green NS, Barral S. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr. Blood Cancer 56(2), 177-181 (2011).
14. Thein SL, Menzel S, Peng X et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc. Natl Acad. Sci. USA 104(27), 11346-11351 (2007). (Pubitemid 47175143)
15. Roden DM, Altman RB, Benowitz NL et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145(10), 749-757 (2006). (Pubitemid 351650355)
16. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age. Blood 85(4), 1111-1117 (1995).
17. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood 89(3), 1078-1088 (1997). (Pubitemid 27121303)
18. Bakanay SM, Dainer E, Clair BL et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 105(2), 545-547 (2005). (Pubitemid 40070734)
19. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann. Hematol. 83(7), 430-433 (2004). (Pubitemid 38877964)
20. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 89(10), 1172-1178 (2004). (Pubitemid 39390440)
21. Ansari SH, Shamsi TS, Munzir S et al. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. J. Pediatr. Hematol. Oncol. 35(4), e153-e156 (2013).
22. Bradai M, Pissard S, Abad MT et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 47(10), 1830-1836 (2007). (Pubitemid 47438549)
23. Koren A, Levin C, Dgany O et al. Response to hydroxyurea therapy in beta-thalassemia. Am. J. Hematol. 83(5), 366-370 (2008).
24. Italia KY, Jijina FF, Merchant R et al. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. J. Clin. Pathol. 63(2), 147-150 (2010).
25. Dixit A, Chatterjee TC, Mishra P et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann. Hematol. 84(7), 441-446 (2005). (Pubitemid 40867920)
26. Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatr. Hematol. Oncol. 26(8), 560-565 (2009).
27. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int. J. Hematol. 95(1), 51-56 (2012).
28. Rigano P, Pecoraro A, Calzolari R et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br. J. Haematol. 151(5), 509-515 (2010).
29. Banan M, Bayat H, Azarkeivan A et al.The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin 36(4), 371-380 (2012).
30. Ma Q, Wyszynski DF, Farrell JJ et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 7(6), 386-394 (2007). (Pubitemid 350187450)
31. Tafrali C, Paizi A, Borg J et al. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics. 14(5), 469-483 (2013).
32. Flanagan JM, Steward S, Howard TA et al. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br. J. Haematol. 157(2), 240-248 (2012).
33. Borg J, Phylactides M, Bartsakoulia M et al. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics 13(13), 1487-1500 (2012).
34. Kumkhaek C, Taylor JG, Zhu J, Hoppe C, Kato GJ, Rodgers GP. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br. J. Haematol. 141(2), 254-259 (2008). (Pubitemid 351406217)
35. Borg J, Papadopoulos P, Georgitsi M et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat. Genet. 42(9), 801-805 (2010).
36. Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences in drug response. Clin. Pharmacol. Ther. 92(6), 727-736 (2012).
37. Cascorbi I. Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics. Pharmacogenomics 14(15), 1807-1809 (2013).
38. Ware RE, Despotovic JM, Mortier NA et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 118(18), 4985-4991 (2011).
39. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 115(26), 5300-5311 (2010).
40. Haj Khelil A, Morinière M, Laradi S et al. Xmn I polymorphism associated with concomitant activation of Gγ and Aγ globin gene transcription on a β0-thalassemia chromosome. Blood Cells Mol. Dis. 46(2), 133-138 (2011).
41. Ferrara M, Matarese SM, Francese M et al. Role of polymorphic sequences 5́ to the G[gamma] gene and 5́ to the beta gene on the homozygous beta thalassemic phenotype. Hemoglobin 27(3), 167-175 (2003). (Pubitemid 36962050)
42. Jouini L, Sahli CA, Laaouini N et al. Association between clinical expression and molecular heterogeneity in β-thalassemia Tunisian patients. Mol. Biol. Rep. 40(11), 6205-6212 (2013).
43. Galanello R, Sanna S, Perseu L et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood 114(18), 3935-3937 (2009).
44. Nuinoon M, Makarasara W, Mushiroda T et al. A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum. Genet. 127(3), 303-314 (2010).
45. Giannopoulou E, Bartsakoulia M, Tafrali C et al. A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype. Hemoglobin 36(5), 433-445 (2012).
46. Pourfarzad F, von Lindern M, Azarkeivan A et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica 98(5), 696-704 (2013).
47. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann NY Acad. Sci. 1054, 124-135 (2005). (Pubitemid 43031017)